Adocia
Products and platforms
- Pipeline
- Technology Platforms
Careers
Partnering
Investors
Media
Contact
- Contact us
- Map and accessibility

Investors
Media
- Press releases
- Media

EN
- FR

Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300

Previous articleAdocia to Present Successful Clinical Results for BioChaperone® Lispro and BioChaperone® Combo at the American Diabetes Association 74th Scientific Sessions on June 15th 2014

Next article“The Ultra-Rapid BioChaperone® Insulin Lispro shows a Faster Onset of Action and Stronger Early Metabolic Effect than Native Insulin Lispro” (Poster 78-LB), presented by Dr. Grit Anderson, 74th Scientific Sessions of the American Diabetes Association, 13-17 June 2014, San Francisco, CA (USA)

Adocia
Products and platforms
Careers
Partnering
Investors
Media
Contact

Contact us

+33(0)4 72 610 610 contact@adocia.com

Adocia
115 Avenue Lacassagne
69003 Lyon, France

2026 © Adocia

Site plan
Legal notice
Privacy policy and cookies policy
Managing cookies

Website by

Un Brin de Campagne